Stock AnalizGuardant Health (GH) earnings for the quarter ended September 2026: EPS beats estimates
Guardant Health reported results for the quarter ended September 2026 on November 5, 2026. Adjusted earnings per share came in at -$0.29 against the analysts’ average forecast of -$0.31, a beat of 6.4%.
Revenue for the quarter was $361 million, up 36.1% from $265 million in the same quarter a year earlier.
The market’s verdict: the stock fell 10.5% on the first trading day after the report.
The last four quarters
Guardant Health has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$0.29 | -$0.31 | +6.4% | +36% | −10.5% |
| Jun 2026 | -$0.42 | -$0.39 | −7.8% | +44% | +12.4% |
| Mar 2026 | -$0.45 | -$0.47 | +5.0% | +48% | +3.7% |
| Sep 2025 | -$0.39 | -$0.49 | +20.3% | +39% | +32.8% |
What comes next
Analysts expect EPS of -$0.30 for the next quarter on average and -$1.45 for the fiscal year ending December 31, 2026.
The average analyst price target is $200.76, 32% above the current price of $151.70.
Valuation and score
Guardant Health scores 1.2 out of 5 overall on Stock Analiz (weak), and its intrinsic value under moderate assumptions is about 94% below the current market value. Full Guardant Health analysis with 10 years of financials
Frequently asked questions
What was Guardant Health’s EPS for the quarter ended September 2026?
-$0.29 adjusted per share, against an analyst consensus of -$0.31.
How much revenue did Guardant Health report?
$361 million, up 36.1% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.